The research suggests that pioglitazone's ability to reduce inflammation helps wounds heal faster and prevents ulcers from forming. However, since the drug can cause side effects, like weaker ...

Combination therapy with GLP-1 RAs and thiazolidinediones is associated with a reduced risk for mortality in patients with T2D, a study finds.

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

A small clinical trial in China suggests that a low-dose vitamin E supplement could improve liver tissues and scarring for ...

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this ...

In summary, GLP-1 receptor agonists, originally used to treat diabetes, are now being explored for brain protection. Two ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...

A new study published in the Journal of American Medical Association showed that glucagon-like peptide-1 receptor agonists ...

A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.

Dementia, including Alzheimer’s disease and related disorders, is one of the fastest-growing public health concerns globally. It currently affects over 55 million people and is expected to impact 139 ...

Weight-loss jabs and those for diabetes may be linked to a lower risk of dementia, a study suggests. Semaglutide in ...